Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. CSL Limited
  6. Summary
    CSL   AU000000CSL8

CSL LIMITED

(CSL)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Australian Stock Exchange
06/11/2021 06/15/2021 06/16/2021 06/17/2021 06/18/2021 Date
296.64 301.72 302.9 302.22 305.52 Last
403912 674189 698597 959068 2097017 Volume
+0.48% +1.71% +0.39% -0.22% +1.09% Change
Financials (USD)
Sales 2021 10 080 M - -
Net income 2021 2 294 M - -
Net Debt 2021 4 209 M - -
P/E ratio 2021 45,4x
Yield 2021 0,89%
Sales 2022 10 469 M - -
Net income 2022 2 371 M - -
Net Debt 2022 4 016 M - -
P/E ratio 2022 43,9x
Yield 2022 0,98%
Capitalization 104 B 104 B -
EV / Sales 2021 10,7x
EV / Sales 2022 10,3x
Nbr of Employees 27 000
Free-Float 99,8%
More Financials
Company
CSL Limited is an Australia-based biotechnology company engaged in the developing and delivering medicines that treat people with rare diseases. It offers treatments for people who are living with conditions in the immunology and neurology; haematology and thrombosis; cardiovascular and metabolic; respiratory, and transplant therapeutic areas. Its segment includes CSL Behring and Seqirus. CSL Behring segment... 
Read more
Sector
Pharmaceuticals
Calendar
08/18Earnings Release
More about the company
Ratings of CSL Limited
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about CSL LIMITED
06/18Australia shares end higher on tech, healthcare boost
RE
06/09Australian shares inch higher on tech gains; U.S. inflation data eyed
RE
06/09CSL  : Hizentra (Immune Globulin Subcutaneous 20% Liquid) To Be Covered Under Me..
AQ
06/08Australia shares off record peak as focus shifts to U.S. data
RE
06/04Financials lift Aussie stocks to all-time high for third day on GDP data boos..
RE
05/31CSL  : Applications Open for Fellowships
PU
05/24Australian shares rise to two-week high as energy stocks rally
RE
05/20Tech rally, upbeat job data help Australia shares extend gains
RE
05/19Australia shares recover on financial, tech boost
RE
05/12CSL  : California Adds New Residential Remodeling Contractor License Classificat..
AQ
05/11CSL  : welcomes the Patent Box Policy
PU
05/11CSL  : welcomes domestic mRNA vaccine development
PU
05/07UNIQURE N  : CSL Behring Announces Closing of Global Commercialization and Licen..
AQ
05/06Australia shares flat as healthcare, tech stocks cap gains in miners
RE
05/06CSL  : Behring Announces Agreement with uniQure
PU
More news
News in other languages on CSL LIMITED
05/05MÄRKTE ASIEN/Schwache US-Vorgaben dämpfen Kauflaune
04/09Australia duplica el pedido de vacunas de Pfizer tras el revés de AstraZeneca
04/07SCOTT MORRISON : L'Australie appelle l'UE à livrer des vaccins, si blocage il n'..
04/06ASTRAZENECA  : L'Australie appelle l'UE à livrer des vaccins, si blocage il n'y ..
04/06ASTRAZENECA  : L'Australie dit que l'UE lui a demandé de retirer sa demande d'ex..
More news
Analyst Recommendations on CSL LIMITED
More recommendations
Analysis
AstraZeneca shares fall on 'hefty' $39-billion Alexion deal
Chart CSL LIMITED
Duration : Period :
CSL Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CSL LIMITED
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 14
Average target price 235,11 $
Last Close Price 228,55 $
Spread / Highest target 13,8%
Spread / Average Target 2,87%
Spread / Lowest Target -17,4%
EPS Revisions
Managers and Directors
NameTitle
Paul Roger Perreault Chief Executive Officer, Executive Director & MD
Joy Carolyn Linton Chief Financial Officer
Brian Anthony McNamee Chairman
Andrew Cuthbertson Chief Scientific Officer & Executive Director
William Mezzanotte Chief Medical Officer, EVP & Head-R&D
Sector and Competitors
1st jan.Capitalization (M$)
CSL LIMITED7.89%104 078
WUXI BIOLOGICS (CAYMAN) INC.28.50%71 827
BIOGEN INC.58.64%58 481
SAMSUNG BIOLOGICS CO.,LTD.1.21%48 692
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.21.49%44 555
ALEXION PHARMACEUTICALS, INC.15.65%39 936